Therapeutic pipeline in nonalcoholic steatohepatitis
The DOI matches its Crossref record; 191 of the 191 references it cites were found in a registry or an index.
Abstract
Our understanding of nonalcoholic fatty liver disease pathophysiology continues to advance rapidly. Accordingly, the field has moved from describing the clinical phenotype through the presence of nonalcoholic steatohepatitis (NASH) and degree of fibrosis to deep phenotyping with a description of associated comorbidities, genetic polymorphisms and environmental influences that could be associated with disease progression. These insights have fuelled a robust therapeutic pipeline across a variety of new targets to resolve steatohepatitis or reverse fibrosis, or both. Additionally, some of these therapies have beneficial effects that extend beyond the liver, such as effects on glycaemic control, lipid profile and weight loss. In addition, emerging therapies for NASH cirrhosis would have to demonstrate either reversal of fibrosis with associated reduction in portal hypertension or at least delay the progression with eventual decrease in liver-related outcomes. For non-cirrhotic NASH, it is the expectation that reversal of fibrosis by one stage or resolution of NASH with no worsening in fibrosis will need to be accompanied by overall survival benefits. In this Review, we summarize NASH therapies that have progressed to phase II and beyond. We also discuss some of the potential clinical challenges with the use of these new therapies when approved.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Steatosis does not define the degree of fibrosis nor the progression of the disease, but reversal of fibrosis is often observed with weight loss of >10% in obese patients with NAFLD.9,10”
From Understanding the cellular interactome of non-alcoholic fatty liver disease (2022) · cites this paper as [10]
In the citing paper
“Steatosis does not define the degree of fibrosis nor the progression of the disease, but reversal of fibrosis is often observed with weight loss of >10% in obese patients with NAFLD.9,10”
From Understanding the cellular interactome of non-alcoholic fatty liver disease (2022) · cites this paper as [10]
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationLiraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
Self-citationPioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Self-citationMAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease
Eslam, M., Sanyal, A. J., George, J., Sanyal, A., Neuschwander-Tetri, B., Tiribelli, C., Kleiner, D. E., Brunt, E., Bugianesi, E., Yki-Järvinen, H., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.312 · Cited by 3,286
Self-citationAngulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Self-citation
Research works printed but not linked: 12
- Siemens Healthineers. FDA grants breakthrough device designation to Siemens Healthineers Enhanced Liver Fibrosis (ELF™) Test. Siemens https://www.siemens-healthineers.com/en-us/press-room/press-releases/elftest.html (2018).
- Ratziu, V. et al. One-year results of the global phase 2b randomized placebo-controlled ARREST trial of aramchol, a stearoyl CoA desaturase inhibitor, in patients with NASH [abstract]. Hepatology 68, LB-5 (2018).
- Frenette, C. T. et al. Emricasan (IDN-6556) orally for 6 months in patients with cirrhosis and elevated MELD score improves liver function [abstract]. Hepatology 64, 1042A (2016).
- Lucas, K. J. et al. Safety and efficacy of tropifexor in patients with fibrotic nonalcoholic steatohepatitis: 48-week results from part C of the phase 2 FLIGHT-FXR study [abstract 139]. Hepatology 72, 101A–102A (2020).
- ENANTA Pharmaceuticals. ENANTA announces positive results of ARGON-1 study of its lead FXR agonist, EDP-305, for the treatment of NASH. ENANTA Pharmaceuticals https://www.enanta.com/investors/news-releases/press-release/2019/Enanta-Announces-Positive-Results-of-ARGON-1-Study-of-its-lead-FXR-Agonist-EDP-305-for-the-Treatment-of-NASH/default.aspx (2019).
- Lawitz E, B. M. et al. MET409, an optimized farnesoid X receptor agonist, decreased liver fat and improved liver enzymes in patients with nonalcoholic steatohepatitis: a 12-week, randomized, placebocontrolled study [abstract LB16]. J. Hepatol. 73, S132 (2020).
- Amin, N. et al. PF-05221304 (PF’1304), a liver-targeted acetyl-CoA carboxylase inhibitor (ACCI), in adults with nonalcoholic fatty liver disease (NAFLD) demonstrates robust reductions in liver fat and alt - phase 2a, dose-ranging study [abstract]. Hepatology 70, 21A–22A (2019).
- Harrison, S. A. et al. Efruxifermin (EFX), a long-acting Fc-FGF21 fusion protein, administered for 16 weeks to patients with NASH substantially reduces liver fat and ALT, and improves liver histology: analysis of a randomized, placebo-controlled, phase 2a study (balanced) [abstract]. Hepatology 72, 6A–7A (2020).
- Gilead. Gilead announces topline results from phase 2 ATLAS study in patients with bridging fibrosis (F3) and compensated cirrhosis (F4) due to nonalcoholic steatohepatitis (NASH). Gilead https://www.gilead.com/news-and-press/press-room/press-releases/2019/12/gilead-announces-topline-results-from-phase-2-atlas-study-in-patients-with-bridging-fibrosis-f3-and-compensated-cirrhosis-f4-due-to-nonalcoholic-s (2019).
- CymaBay Therapeutics. CymaBay therapeutics halts clinical development of seladelpar. CymaBay Therapeutics https://ir.cymabay.com/press-releases/detail/476/cymabay-therapeutics-halts-clinical-development-of-seladelpar (2019).
- CymaBay Therapeutics. FDA lifts all clinical holds on seladelpar. CymaBay Therapeutics https://ir.cymabay.com/press-releases/detail/485/fda-lifts-all-clinical-holds-on-seladelpar (2020).
- Younossi, Z. M. et al. The impact of pruritus on patient-reported outcomes (Pros) in patients with non-alcoholic steatohepatitis (NASH) treated with obeticholic acid (OCA) [abstract]. Hepatology 70, 39A–40A (2019).
Cited by
Duell, P. B., Welty, F. K., Miller, M., Chait, A., Hammond, G., Ahmad, Z., Cohen, D. E., Horton, J. D., Pressman, G. S., Toth, P. P., et al. (2022) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atv.0000000000000153 · Cited by 727
Immune cell-mediated features of non-alcoholic steatohepatitis
Huby, T., & Gautier, E. L. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00639-3 · Cited by 573
Peiseler, M., Schwabe, R., Hampe, J., Kubes, P., Heikenwälder, M., & Tacke, F. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.06.012 · Cited by 564
Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment
Llovet, J. M., Willoughby, C. E., Singal, A. G., Greten, T. F., Heikenwälder, M., El-Serag, H. B., Finn, R. S., & Friedman, S. L. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00754-7 · Cited by 354
Challenges and opportunities in NASH drug development
Harrison, S. A., Allen, A. M., Dubourg, J., Noureddin, M., & Alkhouri, N. (2023) · Nature Medicine · doi:10.1038/s41591-023-02242-6 · Cited by 353
Self-citation
Metadata
- Authors
- Vuppalanchi, R., Noureddin, M., Alkhouri, N., & Sanyal, A. J.
- Affiliations
- Indiana University School of Medicine (US)
- Cedars-Sinai Medical Center (US)
- Arizona Liver Health (US)
- Virginia Commonwealth University (US)
- Corresponding author
- Sanyal, Arun J.
- Venue
- Nature Reviews Gastroenterology & Hepatology
- Published
- 2021-02-10
- Volume
- 18
- Issue
- 6
- Pages
- 373-392
- ISSN
- 1759-5045 (ISSN-L)
- 1759-5053
- OpenAlex
- W3126379854
- Cited by
- 278
- References
- 191
- Citations by year
- 2026: 17 · 2025: 31 · 2024: 58 · 2023: 61 · 2022: 80 · 2021: 31
- FWCI
- 8.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Gastroenterology & Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- nonalcoholic steatohepatitis, non-alcoholic fatty liver disease, fibrosis reversal, NASH cirrhosis, drug development, disease pathophysiology, comorbidities, genetic polymorphism, portal hypertension, liver-related outcomes
- MeSH terms
- Drug Development, Clinical Trials as Topic, Drug Therapy, Combination, Humans, Liver Cirrhosis, Disease Progression, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapeutic pipeline in nonalcoholic steatohepatitis. https://app.cochat.ai/papers/10.1038/s41575-020-00408-y
- The paper
- Vuppalanchi, R., Noureddin, M., Alkhouri, N., & Sanyal, A. J. (2021). Therapeutic pipeline in nonalcoholic steatohepatitis. Nature Reviews Gastroenterology & Hepatology. https://doi.org/10.1038/s41575-020-00408-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.